➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKesson
McKinsey
Moodys
Johnson and Johnson
AstraZeneca

Last Updated: September 16, 2021

DrugPatentWatch Database Preview

Trastuzumab; hyaluronidase-oysk - Biologic Drug Details


Email this page to a colleague

« Back to Dashboard

Summary for trastuzumab; hyaluronidase-oysk
Recent Litigation for trastuzumab; hyaluronidase-oysk

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Seagen Inc. v. Daiichi Sankyo Co., Ltd.2020-10-19
Genentech, Inc. v. Samsung Bioepis Co. Ltd.2020-06-28
CELGENE CORPORATION v. DR. REDDY'S LABORATORIES, LTD.2019-07-12

See all trastuzumab; hyaluronidase-oysk litigation

PTAB Litigation
PetitionerDate
GEMoaB Monoclonals GmbH2019-12-20
2018-04-24
Forty Seven, Inc.2018-01-08

See all trastuzumab; hyaluronidase-oysk litigation

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for trastuzumab; hyaluronidase-oysk Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for trastuzumab; hyaluronidase-oysk Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for trastuzumab; hyaluronidase-oysk Derived from Patent Text Search

These patents were identified by searching patent claims

Supplementary Protection Certificates for trastuzumab; hyaluronidase-oysk

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1689846/01 Switzerland ⤷  Free Forever Trial PRODUCT NAME: TRASTUZUMAB ENTANSINE; REGISTRATION NO/DATE: SWISSMEDIC 62892 02.05.2013
90009-8 Sweden ⤷  Free Forever Trial PRODUCT NAME: LAROTRECTINIB,OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, PARTICULARLY LAROTRECTINIB SULFATE INCLUDING LAROTRECTINIB HYDROGEN SULFATE; REG. NO/DATE: EU/1/19/1385 20190923
2020000032 Germany ⤷  Free Forever Trial PRODUCT NAME: POLATUZUMAB VEDOTIN; REGISTRATION NO/DATE: EU/1/19/1388 20200116
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKinsey
Mallinckrodt
Express Scripts
Moodys
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.